Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3

Abstract

The present invention relates to treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol). Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.

1 . A method of decreasing eotaxin levels in a human at risk for or experiencing symptoms of a disease or condition characterized by increased levels of eotaxin comprising: administering an eotaxin-lowering effective amount of 25-OH D3 and observing or appreciating the lessening of the symptoms or the disease or condition. 
     
     
         2 . A method according to  claim 1 , further comprising administering Vitamin D. 
     
     
         3 . A method according to  claim 1  wherein the administering is with a pharmaceutical formulation 
     
     
         4 . A method according to  claim 1  wherein the administering is with a food or nutraceutical. 
     
     
         5 . A method according to  claim 1  wherein the disease or condition is selected from the group consisting of: allergic diseases, inflammatory disorders, non-allergic inflammation and malignancies. 
     
     
         6 . A method according to  claim 5  wherein the disease or condition is selected from the group consisting of: asthma, allergic rhinitis, sinusitis, nasal polyps, eosinophilic esophagitis, inflammatory bowel disease, Crohn's disease, gastric symptoms due to food allergies, gastric parasitic infections, and gastro-esophageal reflux. 
     
     
         7 . Use of 25-OH D3 to manufacture a pharmaceutical, food, or nutraceutical to maintain healthy levels of eotaxin or to reduce levels of eotaxin to healthy levels in a human at risk for or experiencing symptoms of a disease or condition characterized by increased levels of eotaxin. 
     
     
         8 . Use according to  claim 7 , in combination with Vitamin D. 
     
     
         9 . Use according to  claim 7  wherein the use is in the manufacture of a medicament. 
     
     
         10 . Use according to  claim 7  wherein the use is in the maufacture of a food or nutraceutical. 
     
     
         11 . Use according to  claim 7  wherein the disease is allergic diseases, inflammatory disorders, non-allergic inflammation and malignancies. 
     
     
         12 . Use according to  claim 7  wherein the disease or condition is selected from the group consisting of: asthma, allergic rhinitis, sinusitis, nasal polyps, eosinophilic esophagitis, inflammatory bowel disease, Crohn's disease, gastric symptoms due to food allergies, gastric parasitic infections, and gastro-esophageal reflux.